User login
The American College of Cardiology (ACC), the American Heart Association (AHA), and the Heart Failure Society of America (HFSA) recently issued joint recommendations on 2 new medications for stage C heart failure patients with a reduced ejection fraction. Valsartan/sacubitril, a combination angiotensin receptor–neprilysin inhibitor, and ivabradine, a sinoatrial node modulator, were both approved by the Food and Drug Administration in 2015, but ivabradine has been licensed for a decade in Europe. Although a comprehensive update to ACC/AHA/HSFA heart failure guidelines is still being developed, the focused update is intended to coincide with the release of new European Society of Cardiology heart failure guidelines. Find out what the guideline authors recommend at Cardiology News: http://www.ecardiologynews.com/specialty-focus/heart-failure/single-article-page/guidelines-add-two-new-heart-failure-treatments/98c0b0a2a2e77dac550cdd52953033ea.html.
The American College of Cardiology (ACC), the American Heart Association (AHA), and the Heart Failure Society of America (HFSA) recently issued joint recommendations on 2 new medications for stage C heart failure patients with a reduced ejection fraction. Valsartan/sacubitril, a combination angiotensin receptor–neprilysin inhibitor, and ivabradine, a sinoatrial node modulator, were both approved by the Food and Drug Administration in 2015, but ivabradine has been licensed for a decade in Europe. Although a comprehensive update to ACC/AHA/HSFA heart failure guidelines is still being developed, the focused update is intended to coincide with the release of new European Society of Cardiology heart failure guidelines. Find out what the guideline authors recommend at Cardiology News: http://www.ecardiologynews.com/specialty-focus/heart-failure/single-article-page/guidelines-add-two-new-heart-failure-treatments/98c0b0a2a2e77dac550cdd52953033ea.html.
The American College of Cardiology (ACC), the American Heart Association (AHA), and the Heart Failure Society of America (HFSA) recently issued joint recommendations on 2 new medications for stage C heart failure patients with a reduced ejection fraction. Valsartan/sacubitril, a combination angiotensin receptor–neprilysin inhibitor, and ivabradine, a sinoatrial node modulator, were both approved by the Food and Drug Administration in 2015, but ivabradine has been licensed for a decade in Europe. Although a comprehensive update to ACC/AHA/HSFA heart failure guidelines is still being developed, the focused update is intended to coincide with the release of new European Society of Cardiology heart failure guidelines. Find out what the guideline authors recommend at Cardiology News: http://www.ecardiologynews.com/specialty-focus/heart-failure/single-article-page/guidelines-add-two-new-heart-failure-treatments/98c0b0a2a2e77dac550cdd52953033ea.html.